Zydus Cadila’s generic Trilafon obtains FDA approval

Adult patients with schizophrenia have a new generic treatment available.

The Food and Drug Administration has cleared Zydus Cadila’s perphenazine tablets in dosage strengths of 2 mg, 4 mg, 8 mg, and 16 mg.

The product is the generic of Trilafon tablets.

This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.

The drug will be manufactured at the group’s formulation manufacturing facility at Baddi.